An artificial heart valve or cardiac valve is a one-way valve implanted into the heart of a patient to replace a dysfunctional native heart valve (valvular heart disease). The human heart contains four valves which are tricuspid valve, pulmonic valve, mitral valve, and aortic valve. Their main purpose is to keep blood flowing in one direction through the heart, and from the heart into the major blood vessels connected to it (the pulmonary artery and the aorta). Heart valves can malfunction for a variety of reasons, which can impede the flow of blood through the valve (stenosis) and/or let blood flow backward through the valve (regurgitation). Both processes put a strain on the heart and may lead to serious problems, including heart failure.
COVID-19 scenario analysis:
The infected population is taken care with help of medical supplies and hence the demand for such medical supplies is rising with the growth in patient population. The use of certain respiratory support devices such as atomizer, life-support machine, oxygen generator, and monitor are carried out for primary clinical treatment. Furthermore, COVID-19 has led to growth in demand for medical supplies which can be used as preventive equipment from the spread of disease. There medical supplies include personal protective equipment including masks, gloves, and protective eyeglasses. With rise in number of COVID-19 cases worldwide, the need for medical supplies keeps on rising among, both from healthcare professionals and civil population for precautionary measures. Manufacturers of these products have a chance to capitalize this increased demand of medical supplies to ensure adequate and continuous supply of personal protective equipment in the market.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis
The major factor affecting the market includes the increase in the incidences of the cardiovascular diseases and heart valve diseases in the recent years would propel the market in the forecast period. The surge in the regulatory approvals of the products would boost the industry in the coming years. Furthermore, the rise in funding by government and public-private organizations is anticipated to help the industry grow in the near future. However, the stringent regulations over the installation procedures and the efficiency of the product may impede the market growth.
New product advancements to flourish the market
In April 2019, the U.S. Food and Drug Administration (FDA) had cleared the Boston Scientific Lotus Edge trans-catheter aortic valve system. Delivered via a minimally invasive procedure, this trans-catheter aortic valve replacement (TAVR) technology is approved for patients with severe aortic stenosis who are considered at high risk for surgical valve replacement via open heart surgery. The Lotus Edge valve system is the third TAVR valve to enter the U.S. market.
In May 2016, St. Jude Medical Inc. announced the U.S. launch of its advanced tissue valve, the Trifecta valve with Glide Technology (GT) for the treatment of patients with unhealthy, damaged or malfunctioning aortic heart valves. Designed with feedback from a cohort of international physicians, the Trifecta GT tissue valve offers patients enhanced valve delivery to ease implantation in challenging anatomies and during minimally invasive surgical approaches.
Surge in mergers and acquisitions to boost the market
In December 2015, CryoLife Inc. made an acquisition for the mechanical heart valve space with a $130 million deal to buy On-X Life Technologies. On-X makes an aortic valve replacement and is developing a mitral chord repair device called Chord-X. The acquisition is expected to enhance CryoLife’s size of addressable market in the coming years.
In January 2019, Abbott had revealed plans to buy medical device firm Cephea Valve Technologies, acting on an option it secured in 2015 with the acquisition of Tendyne Holdings. Abbott had made the move in order to reinforce its portfolio of therapies for mitral valve disease, the most common type of heart valve ailment which affects over four million people in the US alone. Particularly, Cephea is currently developing a less invasive technology for the condition in patients, whose diseased mitral valves need to be replaced, delivering an artificial valve through a vein in the leg, restoring normal blood flow and avoiding the need to resort to open-heart surgery.
Key benefits of the report:
- This study presents the analytical depiction of the global Cardiac Valve industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global market share.
- The current market is quantitatively analyzed to highlight the global market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Cardiac Valve Market research report:
- Who are the leading market players active in the Cardiac Valve market?
- What are the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that would help in tasking further strategic steps?
Cardiac Valve Market Report Highlights
| Aspects | Details |
 By Type |
|
 By End User |
|
 By Region |
|
 Key Market Players | Abbott Laboratories Company, St. Jude Medical, Inc, Symetis SA, Lepu Medical Technology Co., Ltd, Edwards Lifesciences Corporation, TTK Healthcare Limited, LivaNova PLC, Jenavalve Technology, Inc, CryoLife, Inc, Colibri Heart Valve, LLC |
 Other Players | Boston Scientific Corporation, Medtronic plc, Braile Biomédica. |
Loading Table Of Content...
